ClinicalTrials.gg
Not yet recruitingNCT07852299Updated Oct 5, 2026

The Effects of a Caffeine Supplement (UBrain) on Cognitive Fatigue After a Virtual Reality Drive Simulation

An interventional study of Caffeine supplement and Placebo in Caffeine, sponsored by University of Padova. Not yet recruiting at 1 site in Italy. Open to male participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by University of Padova · Not applicable, Interventional, and Other

How we know

Updated Oct 5, 2026Primary outcomes revisedTitle changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
8
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
Male
01

Study summary

Motorsport drivers are now widely recognized as athletes in their own right, as they are required to cope with levels of physical and psychological stress comparable to those experienced in more conventional sports. However, cognitive function appears to play a particularly crucial role in motorsport athletes. Indeed, in competitive automobile racing, the ability to achieve and maintain high speeds depends to a large extent on cognitive information-processing abilities rather than solely on physical parameters.

Although these motor-cognitive abilities can be enhanced through specific training and coaching programs targeting both physical and psychological domains, to date, few studies in the scientific literature have investigated the potential psychophysiological benefits of sports supplementation in motorsport athletes. One aspect that warrants further investigation is the use of dietary supplements containing caffeine and nootropic compounds. Indeed, these supplementation has been shown to potentially enhance executive functions and working memory at the central level.

Therefore, the investigation of novel supplementation strategies with potential ergogenic effects on the psychophysiological performance of motorsport drivers remains important for optimizing both central and peripheral adaptations in this specific athletic population. To this end, the dietary supplement (UBrain) was selected for use in the present study.

02

Conditions studied

  • Caffeine

Keywords

  • caffeine
  • cognitive performance
  • nootropics supplement
03

In context

Lead sponsor

University of Padova is the lead sponsor of 215 studies on the registry; 39 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • No evidence of cognitive impairment, defined as a final score of ≥26 on the (MoCA).
  • Previous experience with on-track driving and/or driving simulation

Exclusion criteria

Exclusion Criteria:

  • Medical history, signs, or symptoms of severe, uncontrolled, or unstable diabetes mellitus or cardiovascular, respiratory, hepatic, renal, thyroid, neurological, neuromuscular, peripheral vascular, or disease.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
8 participants (estimated)

Study arms

  • Experimental
    UBrain group

    Ubrain in a supplement containing mostly caffeine and other components. Four pills (daily dose) contain 200 mg of caffeine.

    Dietary Supplement: Caffeine supplement

  • Placebo comparator
    placebo

    The placebo is composed of maltodextrins. Four pills contain 4 gr of carbohydrate.

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementCaffeine supplement

    Participants will attend the laboratory and undergo a battery of cognitive tests using electroencephalography (EEG) (Go/No-Go task, psychomotor vigilance test (PVT), Open-Closed eyes). Subsequently, participants will receive the Ubrain supplement. Participants will then complete a virtual reality (VR)-based driving simulator intervention, consisting of a total of 40 minutes of simulated driving. Finally, the same tests described above will be repeated to assess the effects of the dietary supplement on cognitive fatigue. After a one-week washout period, the treatment groups will be reversed.

  • Dietary supplementPlacebo

    Participants will attend the laboratory and undergo a battery of cognitive tests using electroencephalography (EEG) (Go/No-Go task, psychomotor vigilance test (PVT), Open-Closed eyes). Subsequently, participants will receive the placebo. Participants will then complete a virtual reality (VR)-based driving simulator intervention, consisting of a total of 40 minutes of simulated driving. Finally, the same tests described above will be repeated to assess the effects of the dietary supplement on cognitive fatigue. After a one-week washout period, the treatment groups will be reversed.

06

What researchers measure

Primary outcomes

  1. Cognitive Fatigue

    Cognitive fatigue will be assessed by examining changes in functional connectivity derived from the eyes-open and eyes-closed EEG recordings. Specifically, connectivity measures obtained before and after the driving simulation will be compared to evaluate changes associated with the 40-minute VR driving task. In addition, post-simulation connectivity measures will be compared between the placebo and UBrain conditions to determine whether supplementation attenuates or modulates the neurophysiological changes associated with prolonged cognitive demand. This approach is based on the rationale that sustained cognitive load and mental fatigue may be accompanied by alterations in functional brain connectivity, reflecting changes in the organization and efficiency of large-scale neural networks involved in attention, executive control, and information processing.

    Time frame: baseline and post drive simulation in the same session for both day 1 and day 2

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Dec 2026, 2 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2026
First posted
Oct 1, 2026
StartEst.
Oct 2026
Primary completionEst.
Dec 2026
CompletionEst.
Jan 2027
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary outcomes
1 edited
What changed in the outcomes
  • EditedCogntiveCognitive FatigueTime frame: baseline and post drive simulation in the same session for both day 1 and day 2
Oct 5, 2026
Title
The Effects of a Caffeine Supplement (UBrain) on Cognitive Fatigue After a VRVirtual Reality Drive Simulation
Oct 5, 2026
Registered
First appeared on the registry
Oct 1, 2026
Show all 2 updates
  1. Oct 5, 2026
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedCogntiveCognitive FatigueTime frame: baseline and post drive simulation in the same session for both day 1 and day 2
    Title The Effects of a Caffeine Supplement (UBrain) on Cognitive Fatigue After a VRVirtual Reality Drive Simulation
    + 3 other changes: description, conditions and arm descriptions
  2. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07852299
Responsible party
Sponsor
First posted
Oct 1, 2026
Start date
Oct 2026 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Jan 2027 (estimated)
Last update
Oct 5, 2026

Study contacts

Antonio Paoli
Contact
antonio.paoli@unipd.it
0498275318
Antonio Paoli
study director · University of Padua Department of Biomedical Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion